KUALA LUMPUR: Kenanga Investment Bank Bhd
has announced the world's first structured warrants linked to the Hang Seng Biotech Index (HSBIO) under its flagship brand, NagaWarrants by Kenanga.
In a statement, it said the warrants, HSBIO-CAA (0661AA) and HSBIO-HBA (0661BA), provide Malaysian investors with exposure to Hong Kong’s biotechnology and healthcare sector, one of Asia’s most compelling long-term growth themes driven by demographic shifts, rising healthcare demand and continued medical innovation.
The HSBIO tracks 30 of the largest biotechnology and healthcare companies listed in Hong Kong. The index, which gained 64.5% in 2025, outperformed other Hong Kong benchmarks, including the Hang Seng Index (HSI), Hang Seng China Enterprises Index (HSSCEI) and Hang Seng TECH Index (HSTECH).
"This latest launch underscores our focus on delivering differentiated products that broaden investor choice and provide access to a wider range of market opportunities beyond traditional benchmarks,” said Datuk Chay Wai Leong, group managing director of Kenanga Investment Bank.
Philip Lim Kuok Wei, head of equity markets and group head of equity derivatives of Kenanga Investment Bank, added that HSBIO structured warrants provide investors with a familiar way to gain exposure to biotechnology.
"The addition of HSBIO-CAA and HSBIO-HBA broadens the range of Hong Kong market exposures available through NagaWarrants, complementing existing offerings linked to the HSI, HSCEI and HSTECH," he said.
